Exercise program aims to boost recovery in older transplant patients
NCT ID NCT05612789
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a supervised exercise program can improve recovery and survival in people aged 60 and older receiving a stem cell transplant for blood cancer. Participants will exercise before and after their transplant, with compliance tracked by activity monitors. The main goal is to see if the program is feasible, with secondary goals including hospital stay length and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- supervised exercise program
- What this could lead to
- If it works, this could show that exercise helps older transplant patients recover faster and have better long-term outcomes.
- What could go wrong
- This is a small pilot study focused on feasibility, not proof of benefit. Results may not apply to all patients, and exercise may be difficult for some.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 72 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2023
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Cohort A (Prehab) 1. Age 60 years or older. 2. Planned allogeneic HCT in the next 1-6 months. 3. Hematological malignancy as the indication for HCT. 4. Pre-frail or frail by Fried frailty phenotype. Cohort B (Rehab) 1. Age 60 years or older. 2. Planned allogeneic HCT or HCT within the last 30 days. 3. Hematological malignancy as the indication for HCT. Exclusion Criteria: Cohorts A and B 1\. Comorbid disability or illness that prevents safe exercise.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allogeneic transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Penn Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict lung damage from CAR t-cell therapy?
- Switching stomach drugs after transplant may tame a deadly immune attack
- A guided path back to work after blood cancer: a trial tests the impact
- Could a walk a day keep brain fog away after a stem cell transplant?
- Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication
- Ancient herb takes on transplant complication: Withaferin-A tested for Steroid-Resistant GVHD